Semustine
Phase 3Small molecule
Merck & Co.Semustine is one of 30 small molecule programs targeting Anaplastic Astrocytoma. It is currently in Phase 3.
1
Indications
5
Total Trials
2
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Anaplastic Astrocytoma
#DrugCompanyPhaseTrials
1Gilenya
NovartisApproved
Actos
TakedaApproved
Istodax
TevaApproved
Cialis
Eli LillyApproved
Paraplatin
AAvyxa
Approved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Valtrex
GGlaxo Dba Glaxosmithkline
Approved
Ixempra
RR-Pharm
Approved
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Allogeneic Hematopoietic Stem Cell Transplantation2 trials
Anaplastic Astrocytoma1 trial
Outcome1 trial
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT04945096·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Semustine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company